Immunovant Stock Slides After Biotech Scraps Autoimmune Drug Program — Barrons.com

By Mackenzie TatananniImmunovant shares were on track for their worst session in over a year after the biotech said it was halting development of its experimental autoimmune drug in one indication following a trial miss.Immunovant on Wednesday reported negative results in a proof-of-concept trial f…